The Impact of Oral Glutathione on Oxidative Damage and Glycated Hemoglobin (HbA1c) Levels in Type 2 Diabetes Patients
The Impact of Oral Glutathione on Oxidative Damage and Glycated Hemoglobin (HbA1c) Levels in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study
Sponsor: Center of New Medical Technologies
This NA trial investigates Type 2 Diabetes and is currently completed. Center of New Medical Technologies leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Apr 2025 — Sep 2025 [monthly]
Completed NA
-
Sep 2024 — Apr 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Apr 2024 — Jul 2024 [monthly]
Completed NA
First recorded
Jun 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Center of New Medical Technologies
- S.LAB (SOLOWAYS)
For direct contact, visit the study record on ClinicalTrials.gov .